Cargando…
Epi-Drugs in Heart Failure
Unveiling the secrets of genome’s flexibility does not only foster new research in the field, but also gives rise to the exploration and development of novel epigenetic-based therapies as an approach to alleviate disease phenotypes. A better understanding of chromatin biology (DNA/histone complexes)...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326055/ https://www.ncbi.nlm.nih.gov/pubmed/35911511 http://dx.doi.org/10.3389/fcvm.2022.923014 |
_version_ | 1784757191191822336 |
---|---|
author | Gorica, Era Mohammed, Shafeeq A. Ambrosini, Samuele Calderone, Vincenzo Costantino, Sarah Paneni, Francesco |
author_facet | Gorica, Era Mohammed, Shafeeq A. Ambrosini, Samuele Calderone, Vincenzo Costantino, Sarah Paneni, Francesco |
author_sort | Gorica, Era |
collection | PubMed |
description | Unveiling the secrets of genome’s flexibility does not only foster new research in the field, but also gives rise to the exploration and development of novel epigenetic-based therapies as an approach to alleviate disease phenotypes. A better understanding of chromatin biology (DNA/histone complexes) and non-coding RNAs (ncRNAs) has enabled the development of epigenetic drugs able to modulate transcriptional programs implicated in cardiovascular diseases. This particularly applies to heart failure, where epigenetic networks have shown to underpin several pathological features, such as left ventricular hypertrophy, fibrosis, cardiomyocyte apoptosis and microvascular dysfunction. Targeting epigenetic signals might represent a promising approach, especially in patients with heart failure with preserved ejection fraction (HFpEF), where prognosis remains poor and breakthrough therapies have yet to be approved. In this setting, epigenetics can be employed for the development of customized therapeutic approaches thus paving the way for personalized medicine. Even though the beneficial effects of epi-drugs are gaining attention, the number of epigenetic compounds used in the clinical practice remains low suggesting that more selective epi-drugs are needed. From DNA-methylation changes to non-coding RNAs, we can establish brand-new regulations for drug targets with the aim of restoring healthy epigenomes and transcriptional programs in the failing heart. In the present review, we bring the timeline of epi-drug discovery and development, thus highlighting the emerging role of epigenetic therapies in heart failure. |
format | Online Article Text |
id | pubmed-9326055 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93260552022-07-28 Epi-Drugs in Heart Failure Gorica, Era Mohammed, Shafeeq A. Ambrosini, Samuele Calderone, Vincenzo Costantino, Sarah Paneni, Francesco Front Cardiovasc Med Cardiovascular Medicine Unveiling the secrets of genome’s flexibility does not only foster new research in the field, but also gives rise to the exploration and development of novel epigenetic-based therapies as an approach to alleviate disease phenotypes. A better understanding of chromatin biology (DNA/histone complexes) and non-coding RNAs (ncRNAs) has enabled the development of epigenetic drugs able to modulate transcriptional programs implicated in cardiovascular diseases. This particularly applies to heart failure, where epigenetic networks have shown to underpin several pathological features, such as left ventricular hypertrophy, fibrosis, cardiomyocyte apoptosis and microvascular dysfunction. Targeting epigenetic signals might represent a promising approach, especially in patients with heart failure with preserved ejection fraction (HFpEF), where prognosis remains poor and breakthrough therapies have yet to be approved. In this setting, epigenetics can be employed for the development of customized therapeutic approaches thus paving the way for personalized medicine. Even though the beneficial effects of epi-drugs are gaining attention, the number of epigenetic compounds used in the clinical practice remains low suggesting that more selective epi-drugs are needed. From DNA-methylation changes to non-coding RNAs, we can establish brand-new regulations for drug targets with the aim of restoring healthy epigenomes and transcriptional programs in the failing heart. In the present review, we bring the timeline of epi-drug discovery and development, thus highlighting the emerging role of epigenetic therapies in heart failure. Frontiers Media S.A. 2022-07-13 /pmc/articles/PMC9326055/ /pubmed/35911511 http://dx.doi.org/10.3389/fcvm.2022.923014 Text en Copyright © 2022 Gorica, Mohammed, Ambrosini, Calderone, Costantino and Paneni. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Gorica, Era Mohammed, Shafeeq A. Ambrosini, Samuele Calderone, Vincenzo Costantino, Sarah Paneni, Francesco Epi-Drugs in Heart Failure |
title | Epi-Drugs in Heart Failure |
title_full | Epi-Drugs in Heart Failure |
title_fullStr | Epi-Drugs in Heart Failure |
title_full_unstemmed | Epi-Drugs in Heart Failure |
title_short | Epi-Drugs in Heart Failure |
title_sort | epi-drugs in heart failure |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326055/ https://www.ncbi.nlm.nih.gov/pubmed/35911511 http://dx.doi.org/10.3389/fcvm.2022.923014 |
work_keys_str_mv | AT goricaera epidrugsinheartfailure AT mohammedshafeeqa epidrugsinheartfailure AT ambrosinisamuele epidrugsinheartfailure AT calderonevincenzo epidrugsinheartfailure AT costantinosarah epidrugsinheartfailure AT panenifrancesco epidrugsinheartfailure |